Poetting Sierk 4
4 · BioNTech SE · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
BioNTech (BNTX) COO Poetting Receives Equity Awards
What Happened
Sierk Poetting, Chief Operating Officer of BioNTech SE (BNTX), received two equity awards on 2026-05-12: 12,586 option units and 10,069 performance share units (PSUs). The Form 4 records these as derivative acquisitions at $0 (standard for grants). The option grant carries an exercise price of EUR 89.38 (subject to an adjustment rule described in the filing). No immediate sale occurred — these are compensatory awards, not open-market purchases or sales.
Key Details
- Transaction date: 2026-05-12; Form 4 filed 2026-05-13 (timely filing).
- Transaction code: A (award/grant); reported acquisition value shown as $0 for each grant (derivative grant).
- Option specifics (12,586 units): exercise price EUR 89.38 (footnote F1); may be settled in ordinary shares, ADSs and/or cash at the supervisory board’s election (F3). Vesting: annual equal installments over 4 years starting on the first anniversary; exercisable after four years subject to performance and other conditions (F2).
- PSU specifics (10,069 units): each PSU equals the economic equivalent of one ordinary share; vesting in equal annual installments over 4 years starting on the first anniversary and becoming exercisable after four years subject to performance targets tied to the Nasdaq Biotechnology Index and continued service (F4). Settlement may be in ordinary shares, ADSs, cash or other form.
- Shares owned after the transaction: not disclosed in the provided filing excerpt.
Context
These awards are typical long-term incentive grants for executives. Options require a future exercise (and payment of the exercise price) and PSUs vest only if service and performance conditions are met, so they do not represent immediately tradable shares or cash. Such grants are intended for retention and performance alignment and do not, by themselves, signal an insider buying or selling shares.
Insider Transaction Report
- Award
Option (right to buy)
[F1][F2][F3]2026-05-12+12,586→ 12,586 totalFrom: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (12,586 underlying) - Award
Performance Share Unit
[F4]2026-05-12+10,069→ 10,069 totalExercise: $0.00From: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (10,069 underlying)
Footnotes (4)
- [F1]The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.
- [F2]The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
- [F3]The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.
- [F4]Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.